SCHEMBL1421329

SCHEMBL1421329

O=C(O)c1nc(CO)cs1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 1/20 0.40
GABRB2 P47870 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PLA2G4A P47712 1/20 0.36
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
RAB9A P51151 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 1/20 0.33
NUDT1 P36639 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
PKM P14618 1/20 0.33
KDM4E B2RXH2 1/20 0.32
PRNP P04156 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1244982 0.82 PLA2G4A (0.41) GABRA5GABRB2HSD17B10PLA2G4AKMT2A
SCHEMBL128514 0.82 GABRA5 (0.39) GABRA5GABRB2HSD17B10PLA2G4AKMT2A
SCHEMBL4911470 0.82 KMT2A (0.39) GABRA5GABRB2HSD17B10KMT2AMEN1
SCHEMBL4890454 0.82 SMN1; SMN2 (0.50) GABRA5GABRB2HSD17B10PLA2G4AKMT2A
SCHEMBL1614004 0.82 ALDH1A1 (0.39) GABRA5GABRB2HSD17B10PLA2G4AKMT2A
SCHEMBL17006970 0.82 GABRA5 (0.39) GABRA5GABRB2HSD17B10PLA2G4AKMT2A
SCHEMBL22685319 0.80 HDAC1 (0.36) GABRA5GABRB2HSD17B10PLA2G4AKMT2A
SCHEMBL19718381 0.79 KDM4E (0.39) GABRA5GABRB2HSD17B10KMT2AMEN1
SCHEMBL2877357 0.79 PLA2G4A (0.43) GABRA5GABRB2HSD17B10PLA2G4AKMT2A
Formaldehyde SCHEMBL28793964 0.79 SMN1; SMN2 (0.47) GABRA5GABRB2HSD17B10PLA2G4AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108064224-A Amide-substituted thiazoles as modulators of Ror gamma t 詹森药业有限公司 2018-05-22 CN disclosed
EP-3212643-A1 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt Janssen Pharmaceutica, N.V. (BE) 2017-09-06 EP disclosed
EP-2778156-B1 Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states ASTRAZENECA AB (SE) 2016-11-30 EP disclosed
WO-2016069974-A1 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt JANSSEN PHARMACEUTICA NV (BE) 2016-05-06 WO disclosed
EP-2778156-A1 Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states AstraZeneca AB (Publ) (SE) 2014-09-17 EP disclosed
CN-102105448-B Phenoxypyridinylamide derivatives and use thereof in the treatment of PDE4 mediated disease states ASTRAZENECA AB 2013-11-13 CN disclosed
US-8273774-B2 Phenoxypyridinylamide compounds ASTRAZENECA AB (SE) 2012-09-25 US disclosed
CN-102105448-A Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states ASTRAZENECA AB 2011-06-22 CN disclosed
EP-2297106-A1 PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES AstraZeneca AB (SE) 2011-03-23 EP disclosed
US-20100041638-A1 Chemical Compounds 293 ASTRAZENECA AB (SE) 2010-02-18 US disclosed
WO-2009144494-A1 PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES ASTRAZENECA AB (SE) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041638-A1 Chemical Compounds 293 PDE4B, PDE4A, PDE3B GABRA5 2666/4885GABRB2 2388/4885HSD17B10 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.